Article Text

Download PDFPDF
Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel
  1. Amanda N. Fader, MD and
  2. Peter G. Rose, MD
  1. Department of Gynecology and Obstetrics, The Cleveland Clinic, Cleveland, OH.
  1. Address correspondence and reprint requests to Amanda Nickles Fader, MD, Department of Gynecology and Obstetrics, The Cleveland Clinic, Bldg A81, 9500 Euclid Ave, Cleveland, OH 44195. E-mail: amanditan{at}


Background: Paclitaxel is used in the treatment of most gynecologic malignancies. It is solubilized in Cremophor EL, a polyoxyethylated castor oil agent responsible for the high rate of paclitaxel-associated hypersensitivity reactions. Abraxane, a newer, Cremophor-free form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers.

Case Reports: Five patients with gynecologic cancers (2 ovarian, 2 endometrial, and 1 cervical malignancy) received Abraxane after having a hypersensitivity reaction to paclitaxel. All five patients tolerated Abraxane well, experiencing no reactions or major side effects to the drug.

Discussion: Abraxane is well tolerated in women with gynecologic cancer who have experienced a paclitaxel-associated hypersensitivity reaction. Further studies are ongoing to determine the clinical activity of Abraxane in the treatment of these malignancies.

  • Paclitaxel
  • Hypersensitivity reaction
  • Abraxane
  • Chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.